Skip to main
MBOT
MBOT logo

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc has recently improved its financial position through successful equity financings and option exercises, leading to increased financing income to $284K for the quarter and $611K year-to-date, compared to prior figures. The company's strategic expansion of its commercial and production capabilities, alongside positive feedback from healthcare providers regarding the LIBERTY Endovascular Robotic System, positions it well for a successful market rollout anticipated in 2Q26. Additionally, the partnership with a third-party logistics provider enhances operational readiness, suggesting strong potential for growth and justifying a premium market valuation as the company prepares for significant upcoming product launches.

Bears say

Microbot Medical Inc. faces significant risks that contribute to a negative outlook on its stock, primarily due to potential delays in the commercialization of its LIBERTY Endovascular Robotic System and unsuccessful expansion into cardio and neuro applications. The company's lack of profitability in the near term, compounded by reimbursement challenges and slow adoption rates, raises concerns about its financial sustainability. Additionally, setbacks in securing international regulatory approvals and insufficient data from randomized controlled trials further exacerbate the uncertainties surrounding its market potential.

Microbot Medical (MBOT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Dec 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.